Antiangiogenic strategies for treatment of malignant gliomas
نویسندگان
چکیده
منابع مشابه
New treatment strategies for malignant gliomas.
Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional therapy of surgery, radiation and chemotherapy is largely palliative. Essentially,...
متن کاملNew Treatment Strategies for Malignant Gliomas
Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical tria...
متن کاملEndogenous inhibitors of angiogenesis in malignant gliomas: Nature’s antiangiogenic therapy1
Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm3. This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are found in the body. Some of these are synthesized by specifi c cells in different organs, and others are cr...
متن کاملEndogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.
Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm(3). This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are found in the body. Some of these are synthesized by specific cells in different organs, and others are c...
متن کاملAdvances in the treatment of malignant gliomas.
Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval by the US Food and Drug Administration as a single agent for recurrent glioblastoma. Recent trial...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurotherapeutics
سال: 2009
ISSN: 1933-7213,1878-7479
DOI: 10.1016/j.nurt.2009.04.010